12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Axanum low dose aspirin/esomeprazole magnesium combination product regulatory update

AstraZeneca withdrew an NDA for Axanum aspirin/esomeprazole to reduce the risk of low-dose aspirin-associated gastric and/or duodenal...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >